Galmed Pharmaceuticals Ltd. (GLMD)
Automate Your Wheel Strategy on GLMD
With Tiblio's Option Bot, you can configure your own wheel strategy including GLMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GLMD
- Rev/Share 0.0
- Book/Share 9.4831
- PB 0.1888
- Debt/Equity 0.0
- CurrentRatio 9.0194
- ROIC -0.3592
- MktCap 4041874.0
- FreeCF/Share -2.9314
- PFCF -0.7748
- PE -0.4337
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4633
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments.
Read More
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models. The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.
Read More
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). The new formulation is expected to offer alternatives to both approved injectable semaglutide (Ozempic© and Wegovy©) and oral form (Rybelsus©), providing a non-invasive route that allows the medication to enter the bloodstream through the oral mucous membranes.
Read More
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
TEL AVIV, Israel , March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol.
Read More
About Galmed Pharmaceuticals Ltd. (GLMD)
- IPO Date 2014-03-13
- Website https://www.galmedpharma.com
- Industry Biotechnology
- CEO Allen Baharaff
- Employees 3